Experts from the Uniformed Services University of the Health Sciences conclude that future battlefield medicine efforts should focus on newer analgesics like DSUVIA® across military settings and establish protocols for
/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.
AcelRx Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ACRX) Q2 2022 Earnings Conference Call August 11, 2022, 04:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Pamela.
Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 2022; fifth.
/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of.